The consensus price target for Cullinan Therapeutics, Inc. (NASDAQ: CGEM) has slightly decreased over the past year but remains stable in recent months.Morgan Stanley analysts have set a price target of $19 for CGEM, indicating a positive outlook for the stock.Cullinan's focus on developing therapies for cancer and immune-related diseases positions it well in the competitive biopharmaceutical industry.Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a clinical-stage biopharmaceutical company that focuses on de ...

Core Insights - Several small-cap biotech and healthcare stocks experienced significant gains in after-hours trading on November 28, 2025, despite a lack of new news [1] Company Summaries - **BioAtla Inc. (BCAB)**: Shares surged 13.94% to $1.03 after closing at $0.9040, up 6.27%. The increase may be linked to financing agreements announced on November 21, including a $7.5 million advance and a Standby Equity Purchase Agreement allowing for the sale of up to $15 million in common stock at a 3% discount [2] - **Metagenomi Inc. (MGX)**: Stock rose 5.71% to $1.85 after a 3.55% gain to $1.75 during regular trading. The movement appears driven by investor sentiment or technical factors, with no new corporate updates [3] - **PAVmed Inc. (PAVM)**: Advanced 5.72% to $0.3900, recovering from a slight decline earlier in the day. The company reported a GAAP net loss of $6.3 million, or $(0.29) per share, with revenue dropping sharply to $5,000 from $996,000 year-over-year [4] - **Precision BioSciences, Inc. (DTIL)**: Gained 2.94% to $5.60, building on a 6.46% rise to $5.44. The company is set to present Phase 1 data from its ELIMINATE-B trial at the Hep-DART 2025 meeting, which may be boosting investor optimism [5] - **Reviva Pharmaceuticals Holdings, Inc. (RVPH)**: Edged up 2.04% to $0.57 after a 7.66% gain to $0.5625. The company narrowed its quarterly net loss to $4.0 million, or $0.06 per share, compared to $8.4 million, or $0.25 per share, in the prior year [6] - **Sonnet BioTherapeutics Holdings, Inc. (SONN)**: Rose 5.11% to $3.91, recovering from a 10.47% decline earlier in the day. The company adjourned a special meeting to allow more time for voting on a proposed combination with Hyperliquid Strategies Inc. and Rorschach I LLC, with over 95% of shares voting in favor [7] - **Entero Therapeutics, Inc. (ENTO)**: Gained 3.68% to $3.10 after a 5.28% rise to $2.99. The company announced a rebranding to GridAI Technologies Corp., effective December 1, 2025, following its acquisition of GRID AI Corp. The new ticker symbol "GRDX" will debut on the Nasdaq Capital Market [8]

Core Insights - Precision BioSciences, Inc. is a clinical stage gene editing company focused on developing in vivo gene editing therapies for diseases with high unmet needs [1] Company Announcement - The company announced it will deliver an oral presentation at the Hep-DART 2025 meeting scheduled for December 7–11, 2025, in Honolulu, Hawaii [1] - The presentation will showcase data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV [1]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - VCI Global Limited (VCIG) is up 57% at $2.79 [3] - The Beachbody Company, Inc. (BODI) is up 29% at $6.52 [3] - Cycurion, Inc. (CYCU) is up 29% at $3.41 [3] - BigBear.ai Holdings, Inc. (BBAI) is up 19% at $6.82 [3] - Hallador Energy Company (HNRG) is up 17% at $23.60 [3] - The RealReal, Inc. (REAL) is up 15% at $12.92 [3] - Galecto, Inc. (GLTO) is up 12% at $19.45 [3] - LivePerson, Inc. (LPSN) is up 12% at $5.87 [3] - Rocket Lab Corporation (RKLB) is up 9% at $56.80 [3] - Babcock & Wilcox Enterprises, Inc. (BW) is up 5% at $7.33 [3] Premarket Losers - Vor Biopharma Inc. (VOR) is down 31% at $12.81 [4] - Outset Medical, Inc. (OM) is down 27% at $8.81 [4] - Comtech Telecommunications Corp. (CMTL) is down 15% at $2.54 [4] - Laird Superfood, Inc. (LSF) is down 10% at $3.69 [4] - CoreWeave, Inc. (CRWV) is down 9% at $95.41 [4] - Gemini Space Station, Inc. (GEMI) is down 8% at $15.33 [4] - Precision BioSciences, Inc. (DTIL) is down 8% at $5.56 [4] - iOThree Limited (IOTR) is down 8% at $3.43 [4] - SenesTech, Inc. (SNES) is down 8% at $3.19 [4] - Life360, Inc. (LIF) is down 6% at $87.00 [4]

Economic Indicators - The U.S. Bureau of Labor Statistics has recalled some workers to prepare the September inflation data despite the ongoing government shutdown, which has raised doubts about the timing of its release originally scheduled for October 15 [3][4] - The inflation report may now be released in time for the Federal Reserve's monetary policy meeting on October 28-29, as the White House Office of Management and Budget has requested the BLS to expedite the process [4] Consumer Trends - Piper Sandler Companies released its 50th semi-annual "Taking Stock With Teens" survey, indicating that Nike remains the top clothing and footwear brand among teenagers, followed by Hollister and Adidas [9] - In the beauty category, e.l.f. Cosmetics continues to lead, while Sephora is the preferred beauty shopping destination for teens [10] - Teenage spending is significant, influencing both direct economic contributions and household purchasing decisions, with billions spent annually [11] Corporate Developments - Instagram's head, Adam Mosseri, has indicated that the company is exploring the development of a standalone TV app to enhance its video content offerings and compete with platforms like YouTube [12][13] - Mosseri believes that existing vertical video content on Instagram could be adapted for a TV format, suggesting a strategic pivot towards video consumption [14]

Economic Indicators - The U.S. Bureau of Labor Statistics has recalled some workers to prepare the September inflation data despite the ongoing government shutdown, which has raised doubts about the timing of its release originally scheduled for October 15 [3][4] - The inflation report may now be released in time for the Federal Reserve's monetary policy meeting on October 28-29, as the White House Office of Management and Budget has requested the BLS to expedite the process [4] Consumer Trends - Piper Sandler Companies released its 50th semi-annual "Taking Stock With Teens" survey, indicating that Nike remains the top clothing and footwear brand among teenagers, followed by Hollister and Adidas [9] - In the beauty category, e.l.f. Cosmetics continues to dominate, while Sephora is the preferred beauty shopping destination for teens [10] - Teenage spending is significant, influencing both direct economic contributions and household purchasing decisions, with billions spent annually [11] Media and Technology - Instagram's head, Adam Mosseri, has indicated the company is exploring the development of a standalone TV app to enhance its video content offerings and compete with platforms like YouTube [12][13] - Mosseri believes that existing vertical video content on Instagram could be adapted for a TV format, reflecting a strategic pivot towards video consumption [12]

Company Overview - Immunome, Inc. (IMNM) shares increased by 6.1% to close at $11.2, supported by higher trading volume compared to normal sessions [1] - The stock has gained 3.9% over the past four weeks [1] Pipeline and Development - The price surge is linked to growing investor optimism regarding the development of varegacestat, the company's lead pipeline candidate, currently in late-stage studies for treating desmoid tumors [2] - Immunome is also working on other targeted therapies in early-stage studies for various cancer indications [2] Financial Expectations - The company is projected to report a quarterly loss of $0.57 per share, reflecting a year-over-year increase of 26.9% [3] - Expected revenues are $2.93 million, which is a 0.7% increase from the same quarter last year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating a lack of earnings estimate revisions [4] Industry Context - Immunome operates within the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Precision BioSciences (DTIL) [4] - Precision BioSciences' consensus EPS estimate has also remained unchanged at -$0.31, showing a year-over-year change of 89.1% [5]

Company Performance - Immunome, Inc. reported a quarterly loss of $0.5 per share, which was better than the Zacks Consensus Estimate of a loss of $0.52, representing an earnings surprise of +3.85% [1] - The company posted revenues of $4.02 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 62.88%, compared to revenues of $2.36 million in the same quarter last year [2] - Over the last four quarters, Immunome has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] Future Outlook - The sustainability of Immunome's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - The current consensus EPS estimate for the upcoming quarter is -$0.56 on revenues of $2.48 million, and for the current fiscal year, it is -$2.21 on revenues of $5.47 million [7] - The estimate revisions trend for Immunome was unfavorable ahead of the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Immunome belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - Another company in the same industry, Precision BioSciences, is expected to report a quarterly loss of $0.09 per share, reflecting a year-over-year change of -102.6%, with revenues anticipated to be $13.7 million, down 72.6% from the previous year [9][10]

分组1 - Qiagen reported quarterly earnings of $0.6 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.57 per share a year ago [1] - The company posted revenues of $533.54 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 1.80%, and up from $496.35 million year-over-year [2] - Qiagen has surpassed consensus revenue estimates four times over the last four quarters [2] 分组2 - The stock has gained approximately 9.7% since the beginning of the year, outperforming the S&P 500's gain of 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.58 on revenues of $517.95 million, and for the current fiscal year, it is $2.35 on revenues of $2.06 billion [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Viewpoint - Precision BioSciences' shares surged 23.8% following the FDA's Fast Track designation for PBGENE-HBV, a gene editing program aimed at curing chronic hepatitis B by targeting cccDNA and integrated HBV DNA [1][2][3] Company Overview - PBGENE-HBV is the first gene editing program with a unique mechanism of action to enter clinical stages as a potential cure for chronic hepatitis B [3] - The company has received FDA clearance to initiate the phase I ELIMINATE-B study for PBGENE-HBV in the U.S., with simultaneous studies in other regions to enhance patient recruitment [4] - Currently, the company is enrolling patients in the low-dose cohort of the ELIMINATE-B study, with plans to escalate to higher doses in subsequent cohorts [5][7] Market Context - Chronic hepatitis B affects approximately 300 million people globally, with around 2 million in the U.S. facing significant health risks, including cirrhosis and liver cancer [8] - Existing antiviral treatments do not eliminate the virus, necessitating lifelong therapy without achieving a functional cure, highlighting the unmet medical need that PBGENE-HBV aims to address [9] Pipeline and Future Prospects - In addition to PBGENE-HBV, Precision BioSciences has several other gene therapy programs in preclinical evaluation, including a partnered candidate, ECUR-506, for treating neonatal onset ornithine transcarbamylase deficiency [10]